Promising Research

The following studies are underway in the late stages of research. We're watching them closely.

MS

April 11, 2022
BTK Inhibitors and Novel Approaches to Multiple Sclerosis

https://www.neurologylive.com/view/btk-inhibitors-and-novel-approaches-to-multiple-sclerosis 

October 20, 2020
Anti-inflammatory therapy shows promise in slowing progression of multiple sclerosis

https://www.sciencedaily.com/releases/2020/10/201020131338.htm 

December 20, 2020
Researchers have identified an immune cell in mice that promotes axon regeneration and neuronal survival and could potentially be harnessed as a treatment for brain, spinal cord, and optic nerve damage.

https://journals.lww.com/neurotodayonline/Fulltext/2020/12030/A_Newly_Identified_Immune_Cell_Promotes_Axon.2.aspx

January 19, 2021
Fatty acid may help combat multiple sclerosis

https://news.yale.edu/2021/01/19/fatty-acid-may-help-combat-multiple-sclerosis

Regrowing Myelin

Simple sugar possible therapy for repairing myelin in multiple sclerosis

https://www.sciencedaily.com/releases/2020/10/201007145416.htm

Mechanisms identified to restore myelin sheaths after injury or in multiple sclerosis 

https://www.sciencedaily.com/releases/2020/08/200824105529.htm

 

Pain

Advances with Long Non-Coding RNAs in Diabetic Peripheral Neuropathy (A peer-reviewed study)

https://www.dovepress.com/advances-with-long-non-coding-rnas-in-diabetic-peripheral-neuropathy-peer-reviewed-fulltext-article-DMSO

Kolon begins testing gene therapy for neuropathic pain in US

http://www.koreabiomed.com/news/articleView.html?idxno=8095

EicOsis EC5026 Granted Fast Track Designation by FDA for Neuropathic Pain

https://www.prnewswire.com/news-releases/eicosis-ec5026-granted-fast-track-designation-by-fda-for-neuropathic-pain-301037943.html

EC5026 just passed Phase 1a Clinical Trial, Nov 15, 2020:

https://www.prnewswire.com/news-releases/eicosis-successfully-completes-phase-1a-clinical-trial-of-ec5026-301174243.html